Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Omnicom Group Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Omnicom Group Inc. trades at $76.48 (market cap $20.97B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 4.19% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Omnicom Group Inc. for 63 Days on average.
| HALO | OMC | |
|---|---|---|
Market Cap | $12.58B | $20.97B |
Volume | 2,179,278 | 2,092,899 |
Sector | Health | Media |
52-Week High | $115.22 | $88.94 |
52-Week Low | $61.63 | $67.27 |
Typical Hold Time | 1 Days | 63 Days |
Enterprise Value | $14.49B | $29.05B |
Dividend Yield | — | 4.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Omnicom Group (OMC) trades at $76.45, up 2.11% with a bullish technical signal despite mixed earnings performance. The company shows strong revenue growth to $17.27B in 2025 but reported a net loss of -$54.5M. Analyst consensus is mixed with 32% buy ratings and a $100.50 price target, while recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings.
OMC presents a value opportunity with attractive P/S of 0.86 and dividend yield, though high P/E of 206.62 and recent net loss pose risks. Upside potential exists from AI capabilities and post-Interpublic synergies, but advertising market weakness and debt levels require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
